Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Dogwood Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 12 | 10 | −2 |
| Shares | 38.9K | 70.2K | +31.3K (+80.5%) |
| Value | $299.5K | $292.0K | −$7.52K (−2.5%) |
New holders (2)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 11,655 | $48.5K | 0.00% |
| UBS Group AG | 1,748 | $7.27K | 0.00% |
Sold out (4)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 744 | $5.73K |
| Citigroup Inc | 99 | $762 |
| Barclays PLC | 5 | $39 |
| SBI Securities Co., Ltd. | 1 | $8 |